Indian arm of Sanofi, leading in insulin-led diabetes care plus cardiovascular, CNS and anti-infective brands.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 |
| Reserves | 2.4k | 2.1k | 2.2k | 1.3k | 992 | 838 | 759 | 726 |
| Borrowings | 0 | 23 | 25 | 24 | 19 | 19 | 21 | 18 |
| Other Liabilities | 802 | 777 | 811 | 772 | 681 | 732 | 436 | 488 |
| Total Liabilities | 3.2k | 2.9k | 3.1k | 2.1k | 1.7k | 1.6k | 1.2k | 1.3k |
| AssetsFixed Assets | 499 | 464 | 334 | 306 | 315 | 312 | 309 | 304 |
| CWIP | 17 | 10 | 13 | 24 | 16 | 18 | 16 | 12 |
| Investments | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Other Assets | 2.7k | 2.4k | 2.7k | 1.7k | 1.4k | 1.3k | 914 | 939 |
| Total Assets | 3.2k | 2.9k | 3.1k | 2.1k | 1.7k | 1.6k | 1.2k | 1.3k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 374 | 412 | 611 | 559 | 399 | 231 | 462 | 438 |
| Cash from Investing | -73 | 66 | 276 | 631 | 651 | 36 | -178 | -11 |
| Cash from Financing | -197 | -183 | -810 | -849 | -1.6k | -878 | -392 | -448 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 317 | 337 | 810 | 574 | 412 | 221 | 426 | 413 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (34.0×) and current (24.8×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At -18.4% growth and a 25× exit, ₹3341 only delivers your return if you pay ₹455. The price is currently baking in 17% growth.
EPS grows -18.4%/yr for 5 years, then fades to 6% over 2, exits at 25×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | -18.4% | 109.92 |
| FY28 | -18.4% | 89.69 |
| FY29 | -18.4% | 73.19 |
| FY30 | -18.4% | 59.72 |
| FY31 | -18.4% | 48.73 |
| FY32 | -6.2% ·fade | 45.71 |
| FY33 | 6.0% ·fade | 48.45 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.